# A Dose-escalation, Expansion Study of ARX788, in Advanced Solid Tumors Subjects With HER2 Expression (ACE-Pan Tumor 01)

> **NCT03255070** · PHASE1 · COMPLETED · sponsor: **Ambrx, Inc.** · enrollment: 106 (actual)

## Conditions studied

- Breast Neoplasms
- Gastric Neoplasm
- Solid Tumors

## Interventions

- **DRUG:** ARX788

## Key facts

- **NCT ID:** NCT03255070
- **Lead sponsor:** Ambrx, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-20
- **Primary completion:** 2023-09-13
- **Final completion:** 2023-10-18
- **Target enrollment:** 106 (ACTUAL)
- **Last updated:** 2024-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03255070

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03255070, "A Dose-escalation, Expansion Study of ARX788, in Advanced Solid Tumors Subjects With HER2 Expression (ACE-Pan Tumor 01)". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03255070. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*